Breast cancer metastasis progression as revealed by intravital videomicroscopy.

abstract：:Novel targeted agents, such as VEGF receptor-tyrosine kinase inhibitors (VEGFR-TKIs) and mTOR inhibitors, have improved therapy for metastatic renal cell carcinoma. Sequential administration of agents with similar mechanisms of action has shown some efficacy in small retrospective studies; however, prospective Phase I...

journal_title：Expert review of anticancer therapy

authors： Larkin J,Swanton C,Pickering L

更新日期：2011-04-01 00:00:00

abstract：:Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamo...

journal_title：Expert review of anticancer therapy

authors： Bria E,Carlini P,Cuppone F,Vaccaro V,Milella M,Cognetti F

更新日期：2010-08-01 00:00:00

abstract：:Genomics has generated a wealth of data that is now being used to identify additional molecular alterations associated with cancer development. Mapping these alterations in the cancer genome is a critical first step in dissecting oncological pathways. There are two ways in which cancer research has changed in recent y...

journal_title：Expert review of anticancer therapy

authors： Sakatani T,Onyango P

更新日期：2003-12-01 00:00:00

abstract：:Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...

journal_title：Expert review of anticancer therapy

authors： Shapiro D,Tareen B

更新日期：2012-07-01 00:00:00

abstract：:Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since...

journal_title：Expert review of anticancer therapy

authors： Warsame R,Grothey A

更新日期：2012-10-01 00:00:00

abstract：:Cancer cells become dangerous when they acquire the ability to invade through physical barriers in the body and disseminate to distant sites. Recent evidence has demonstrated that cancer cells utilize specialized structures called invadopodia, unique protrusions that concentrate proteases such as matrix metalloprotein...

journal_title：Expert review of anticancer therapy

authors： Stoletov K,Lewis JD

更新日期：2015-01-01 00:00:00

abstract：:Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...

journal_title：Expert review of anticancer therapy

authors： Haleblian GE,Wilson C,Haddad D,Albala DM

更新日期：2007-09-01 00:00:00

abstract：:Anemia in cancer patients is frequent but often under-recognized and under-treated. This may be related to misconceptions about the impact of anemia on cancer patients and ill-defined guidelines for treatment, as well as the inadequacies of current therapy. Darbepoetin alfa, a novel erythropoiesis-stimulating protein ...

journal_title：Expert review of anticancer therapy

authors： Pirker R,Smith R

更新日期：2002-08-01 00:00:00

abstract：:Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

journal_title：Expert review of anticancer therapy

authors： Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

更新日期：2004-08-01 00:00:00

abstract：:The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

journal_title：Expert review of anticancer therapy

authors： Espinoza-Delgado I,Childs RW

更新日期：2004-10-01 00:00:00

abstract：:Stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) are advanced radiotherapy delivery techniques that allow for the delivery of high-dose per fraction radiation. Advances in imaging technology and intensity modulation have allowed SRS and SBRT to be used for the treatment of tumors in close prox...

journal_title：Expert review of anticancer therapy

authors： Jain AK,Yamada YJ

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is critical for tumor growth, proliferation and metastasis with the crucial role of Vascular Endothelial Growth factor (VEGF) pathway. Ramucirumab is a monoclonal antibody that specifically targets the extracellular domain of Vascular Endothelial Growth Factor Receptor 2. Areas covered: We per...

journal_title：Expert review of anticancer therapy

authors： Paulus V,Avrillon V,Pérol M

更新日期：2016-11-01 00:00:00

abstract：:Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

journal_title：Expert review of anticancer therapy

authors： Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

更新日期：2010-07-01 00:00:00

abstract：:Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer se...

journal_title：Expert review of anticancer therapy

authors： Braun MS,Quirke P,Seymour MT

更新日期：2007-04-01 00:00:00

abstract：:Waldenström's macroglobulinemia is a distinct disorder characterized by a monoclonal immunoglobulin M paraprotein and morphological evidence of lymphoplasmacytic lymphoma. It is relatively rare, accounting for approximately 2% of all hematological malignancies. The aim of treatment for patients with Waldenström's macr...

journal_title：Expert review of anticancer therapy

authors： Johnson SA

更新日期：2006-03-01 00:00:00

abstract：INTRODUCTION:Endometrial cancer is the most common gynecologic malignancy in the developed world, and its incidence is increasing. Mortality from this cancer has not improved in recent decades and is primarily driven by high-grade carcinomas that are more likely to present at an advanced stage and ultimately are more l...

journal_title：Expert review of anticancer therapy

authors： Connor EV,Rose PG

更新日期：2018-09-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer deaths with a 5-year survival of 4-6%. Clinical challenges remain to be addressed, since few promising approaches to treat pancreatic cancer have been reported. Here we discuss the potential of a new biotherapeutic agent composed of a lysosomal protein (Saposin C...

journal_title：Expert review of anticancer therapy

authors： Olowokure O,Qi X

更新日期：2014-05-01 00:00:00

abstract：:Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

journal_title：Expert review of anticancer therapy

authors： Sigal DS,Saven A

更新日期：2008-04-01 00:00:00

abstract：:The Second European Lung Cancer Conference was held in Geneva, Switzerland from 28 April to 1 May 2010, under the cosponsorship of the International Association for the Study of Lung Cancer and the European Society for Medical Oncology. The main topics included: tobacco control, which represents a crucial challenge fo...

journal_title：Expert review of anticancer therapy

authors： Girard N,Mornex F

更新日期：2010-07-01 00:00:00

abstract：:A number of cancers occur with increased frequency in individuals with HIV infection. There is a debate as to whether or not hepatocellular cancer is one of these tumors. This article reviews the current data regarding incidence etiology, treatment and outcome for HIV-related hepatocellular cancer. It also attempts to...

journal_title：Expert review of anticancer therapy

authors： Powles T,Macdonald D,Nelson M,Stebbing J

更新日期：2006-11-01 00:00:00

abstract：INTRODUCTION:PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K...

journal_title：Expert review of anticancer therapy

authors： Greenwell IB,Flowers CR,Blum KA,Cohen JB

更新日期：2017-03-01 00:00:00

abstract：:Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

journal_title：Expert review of anticancer therapy

authors： Mangat KS,Jeys LM,Carter SR

更新日期：2011-02-01 00:00:00

abstract：:Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer. Optimizing the management of frequent crizotinib-related adverse events is crucial to ensure its continuous administration and reprodu...

journal_title：Expert review of anticancer therapy

authors： Girard N,Audigier-Valette C,Cortot AB,Mennecier B,Debieuvre D,Planchard D,Zalcman G,Moro-Sibilot D,Cadranel J,Barlési F

更新日期：2015-02-01 00:00:00

abstract：:Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

journal_title：Expert review of anticancer therapy

authors： Micali G,Lacarrubba F,Bhatt K,Nasca MR

更新日期：2013-12-01 00:00:00

abstract：INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

journal_title：Expert review of anticancer therapy

authors： Tosoni A,Balestrini D,Brandes AA

更新日期：2017-05-01 00:00:00

abstract：INTRODUCTION:In the last decade tyrosine kinase inhibitors (TKIs) have been employed for a wide range of hematological and solid tumors and today they represent a valid therapeutic option for different neoplasms. Among them, both sorafenib and lenvatinib were approved for the treatment of radioactive iodine (RAI) refra...

journal_title：Expert review of anticancer therapy

authors： Felicetti F,Nervo A,Piovesan A,Berardelli R,Marchisio F,Gallo M,Arvat E

更新日期：2017-12-01 00:00:00

abstract：:Androgen deprivation therapy is the standard of care for the initial treatment of metastatic prostate cancer. However, the majority of these patients live long enough to experience disease progression despite castration. This scenario is defined as castration-resistant prostate cancer (CRPC) and has a poor outcome and...

journal_title：Expert review of anticancer therapy

authors： Gaya JM,Ahallal Y,Sanchez-Salas R,Barret E,Rozet F,Galiano M,Macek P,Durand M,Cerruti J,Prapotnich D,Ropert S,Bennamoun M,Cathelineau X

更新日期：2013-07-01 00:00:00

abstract：:Soft tissue sarcomas are a diverse group of rare tumors that comprise 1% of all cancers. Few randomized trials of chemotherapy have been performed but there is a clear role for agents such as doxorubicin and ifosfamide in the palliation of advanced disease. There is uncertainty as to whether sequential single-agent tr...

journal_title：Expert review of anticancer therapy

authors： Krikelis D,Judson I

更新日期：2010-02-01 00:00:00

abstract：INTRODUCTION:Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until in...

journal_title：Expert review of anticancer therapy

authors： Manceau C,Mourey L,Pouessel D,Ploussard G

更新日期：2020-08-01 00:00:00

abstract：:A large number of different 5-hydroxytryptamine (HT)(3) receptor antagonists have been marketed with the indication of preventing nausea and vomiting induced by chemotherapy--palonosetron is the most recently developed of these. Pharmacologic studies have revealed that palonosetron has a long half-life, a high affinit...

journal_title：Expert review of anticancer therapy

authors： Ruhlmann C,Herrstedt J

更新日期：2010-02-01 00:00:00